88 related articles for article (PubMed ID: 21721201)
21. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
22. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
Ivan D; Niveiro M; Diwan AH; Eton O; Kim KB; Lacey C; Gonzalez C; Prieto VG
J Cutan Pathol; 2006 Apr; 33(4):280-5. PubMed ID: 16630177
[TBL] [Abstract][Full Text] [Related]
23. Targeted molecular therapy in melanoma.
Puzanov I; Flaherty KT
Semin Cutan Med Surg; 2010 Sep; 29(3):196-201. PubMed ID: 21051014
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy and targeted therapy combinations in advanced melanoma.
Flaherty KT
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2366s-2370s. PubMed ID: 16609060
[TBL] [Abstract][Full Text] [Related]
25. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations.
Kirkwood JM; Moschos S; Wang W
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2331s-2336s. PubMed ID: 16609054
[TBL] [Abstract][Full Text] [Related]
26. [Kinase inhibitors for the therapy of malignant melanoma].
Becker JC; Schrama D; Bröcker EB; Houben R
J Dtsch Dermatol Ges; 2005 Oct; 3(10):762-7. PubMed ID: 16194153
[TBL] [Abstract][Full Text] [Related]
27. Novel therapeutics for melanoma.
Seetharamu N; Ott PA; Pavlick AC
Expert Rev Anticancer Ther; 2009 Jun; 9(6):839-49. PubMed ID: 19496721
[TBL] [Abstract][Full Text] [Related]
28. Targeted therapies take aim against lung cancer and melanoma.
Mitka M
JAMA; 2010 Aug; 304(6):624-6. PubMed ID: 20699448
[No Abstract] [Full Text] [Related]
29. [Individualized tumor therapy and status quo in melanoma].
Bauer S; Schmidberger H; Trefzer U
Onkologie; 2012; 35 Suppl 2():2-6. PubMed ID: 22517063
[No Abstract] [Full Text] [Related]
30. Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.
Mangana J; Cheng PF; Kaufmann C; Amann VC; Frauchiger AL; Stögner V; Held U; von Moos R; Michielin O; Braun RP; Levesque MP; Goldinger SM; Dummer R
Melanoma Res; 2017 Aug; 27(4):358-368. PubMed ID: 28509765
[TBL] [Abstract][Full Text] [Related]
31. Understanding melanoma signaling networks as the basis for molecular targeted therapy.
Smalley KS
J Invest Dermatol; 2010 Jan; 130(1):28-37. PubMed ID: 19571822
[TBL] [Abstract][Full Text] [Related]
32. [Experimental treatment of malignant melanoma and its rationale].
Rass K; Diefenbacher M; Tilgen W
Hautarzt; 2008 Jun; 59(6):475-83. PubMed ID: 18449519
[TBL] [Abstract][Full Text] [Related]
33. [Systemic therapy for malignant melanoma].
Rudolph BM; Groffik A; Stanger C; Loquai C; Grabbe S
Hautarzt; 2012 Nov; 63(11):885-98. PubMed ID: 23114509
[TBL] [Abstract][Full Text] [Related]
34. Immunity unleashed in melanoma.
Erdmann MK
Lancet Oncol; 2010 Feb; 11(2):108-9. PubMed ID: 20152761
[No Abstract] [Full Text] [Related]
35. Intralesional therapy for metastatic melanoma.
Sloot S; Rashid OM; Zager JS
Expert Opin Pharmacother; 2014 Dec; 15(18):2629-39. PubMed ID: 25381015
[TBL] [Abstract][Full Text] [Related]
36. Surgical management of metastatic melanoma in the era of targeted systemic therapies.
O'Leary DP; Byrnes KG; Power DG; Redmond HP
Melanoma Res; 2015 Feb; 25(1):1-8. PubMed ID: 25532830
[TBL] [Abstract][Full Text] [Related]
37. Reply to A. Indini et al.
Horvat TZ; Adel NG; Dang TO; Momtaz P; Postow MA; Callahan MK; Carvajal RD; Dickson MA; D'Angelo SP; Woo KM; Panageas KS; Wolchok JD; Chapman PB
J Clin Oncol; 2016 Mar; 34(9):1018-9. PubMed ID: 26786917
[No Abstract] [Full Text] [Related]
38. [Targeted therapeutics and their role in the treatment of internal diseases].
Klener P
Vnitr Lek; 2013 Jan; 59(1):5-12. PubMed ID: 23427997
[TBL] [Abstract][Full Text] [Related]
39. Re: "Drug-induced Graves disease from CTLA-4 receptor suppression".
Sohrab MA; Desai RU; Chambers CB; Lissner GS
Ophthalmic Plast Reconstr Surg; 2013; 29(3):239-40. PubMed ID: 23652294
[No Abstract] [Full Text] [Related]
40. Reply Re: "Drug-induced Graves disease from CTLA-4 receptor suppression".
Borodic GE; Hinkle DM
Ophthalmic Plast Reconstr Surg; 2013; 29(3):241. PubMed ID: 23652295
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
